Vladimir M. Unguryan
Vladimir M. Unguryan has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Anton Nikolaevich Kazantsev
135th Separate Medical Battalion of the Ministry of Defense of the Russian Federation
22 shared publications - Alexander Vladimirovich Korotkikh
Amur State Medical Academy of the Ministry of Health of the Russian Federation (Amur SMA)
15 shared publications - Yuriy V. Belov
Sechenov First Moscow State Medical University (Sechenov University)
15 shared publications - Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
12 shared publications - Sergey Anatolyevich Ivanov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
12 shared publications - Егор Александрович Круглов
Kostroma Oncology Dispensary
8 shared publications
Latest Publications
- 14 May 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (2)
Successful surgical treatment of a patient with locally advanced adrenocortical cancer with prosthetic replacement of the IVC section with cryopreserved allograft using a venovenous bypass shunt
Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex, usually characterized by late detection, aggressive clinical course and unfavorable treatment prognosis. In some cases, patients with ACC have tumor invasion into the IVC, which requires vascular resection of varying extent (longitudinal or circular) with or without subsequent reconstruction. In this article, we report a case of a tumor of the right adrenal gland with tumor thrombosis of the IVC. The patient underwent radical nephradrenalectomy on the right with resection of the inferior vena cava and simultaneous vena cava plastic surgery with cryopreserved allograft under conditions of bypass cava-caval shunting. IVC replacement with cryopreserved allograft using parallel circulation is a rare surgical intervention requiring the work of a multidisciplinary team, with a limited number of cases that can be described in the literature, the authors of this article present this case for consideration.
- 14 May 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (2)
Successful surgical treatment of a patient with locally advanced adrenocortical cancer with prosthetic replacement of the IVC section with cryopreserved allograft using a venovenous bypass shunt
Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex, usually characterized by late detection, aggressive clinical course and unfavorable treatment prognosis. In some cases, patients with ACC have tumor invasion into the IVC, which requires vascular resection of varying extent (longitudinal or circular) with or without subsequent reconstruction. In this article, we report a case of a tumor of the right adrenal gland with tumor thrombosis of the IVC. The patient underwent radical nephradrenalectomy on the right with resection of the inferior vena cava and simultaneous vena cava plastic surgery with cryopreserved allograft under conditions of bypass cava-caval shunting. IVC replacement with cryopreserved allograft using parallel circulation is a rare surgical intervention requiring the work of a multidisciplinary team, with a limited number of cases that can be described in the literature, the authors of this article present this case for consideration.
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Immunotherapy Combined with Stereotactic Radiotherapy or Isolated Hepatic Perfusion for Metastatic Uveal Melanoma: Preliminary Study Results
Введение. Метастатическая увеальная меланома (мУМ) характеризуется неблагоприятным прогнозом и ограниченным числом возможных опций терапии. Одним из основных вариантов лечения лекарственными средствами на сегодняшний день остаются ингибиторы контрольных точек иммунитета (ИКТИ), несмотря на их низкую эффективность. Комбинированные подходы с локальными методами лечения, такими как стереотаксическая лучевая терапия (СТЛТ) или изолированная перфузия печени (ИПП) мелфаланом, потенциально могут продемонстрировать синергизм между собой и тем самым повысить показатели эффективности. Цель. Оценить эффективность и безопасность терапии ингибиторами контрольных точек (анти-PD-1 или анти-PD-1+анти-CTLA-4) в сочетании с СТЛТ или ИПП у пациентов с мУМ. Материалы и методы. Данная работа является продолжающимся несравнительным когортным исследованием. Включались пациенты с ECOG-статусом 0–1 с метастатической увеальной меланомой старше 18 лет, ранее не получавшие системную терапию, имеющие как минимум один измеряемый очаг по критериям RECIST 1.1. Все они получали иммунотерапию (МКА анти-PD-1 монотерапия или комбинация МКА анти-PD-1+анти-CTLA-4) в сочетании с СТЛТ при наличии ≤ 3 метастатических очагов на один орган или ИПП мелфаланом при поражении печени < 50 %; допустимо наличие стабильных метастатических очагов в других органах. Результаты. С сентября 2019 по апрель 2025 г. включено 43 пациента, получавших сочетании ИКТИ и локальных методов (21 — в группу СТЛТ, 22 — в группу ИПП). В группе СТЛТ частота объективного ответа составила 42,8 %, шестимесячная ВБП (выживаемость без прогрессирования) — 66,7 % (95 % ДИ 42,5–82,5); медиана ВБП — 8,6 мес. (95 % ДИ 4,4–13,8), медиана общей выживаемости (ОВ) — 44,7 мес. (95 % ДИ 16,9–НД (не достигнута). В группе ИПП частота объективного ответа составила 45 %, шестимесячная ВБП — 72 % (95 % ДИ 48–86), медиана ВБП — 10,1 мес. (95 % ДИ 5,0–15,5), медиана ОВ не достигнута. Нежелательные явления (НЯ) 3–5-й степени наблюдались у 14,3 (СТЛТ) и 45,5 % (ИПП) пациентов. Выводы. Комбинация ингибиторов контрольных точек иммунитета с СТЛТ или ИПП демонстрирует высокую эффективность и удовлетворительную переносимость при метастатической увеальной меланоме для пациентов с различным объемом метастатического поражения и требует дальнейшего изучения.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessImmunotherapy Combined with Stereotactic Radiotherapy or Isolated Hepatic Perfusion for Metastatic Uveal Melanoma: Preliminary Study Results
Введение. Метастатическая увеальная меланома (мУМ) характеризуется неблагоприятным прогнозом и ограниченным числом возможных опций терапии. Одним из основных вариантов лечения лекарственными средствами на сегодняшний день остаются ингибиторы контрольных точек иммунитета (ИКТИ), несмотря на их низкую эффективность. Комбинированные подходы с локальными методами лечения, такими как стереотаксическая лучевая терапия (СТЛТ) или изолированная перфузия печени (ИПП) мелфаланом, потенциально могут продемонстрировать синергизм между собой и тем самым повысить показатели эффективности. Цель. Оценить эффективность и безопасность терапии ингибиторами контрольных точек (анти-PD-1 или анти-PD-1+анти-CTLA-4) в сочетании с СТЛТ или ИПП у пациентов с мУМ. Материалы и методы. Данная работа является продолжающимся несравнительным когортным исследованием. Включались пациенты с ECOG-статусом 0–1 с метастатической увеальной меланомой старше 18 лет, ранее не получавшие системную терапию, имеющие как минимум один измеряемый очаг по критериям RECIST 1.1. Все они получали иммунотерапию (МКА анти-PD-1 монотерапия или комбинация МКА анти-PD-1+анти-CTLA-4) в сочетании с СТЛТ при наличии ≤ 3 метастатических очагов на один орган или ИПП мелфаланом при поражении печени < 50 %; допустимо наличие стабильных метастатических очагов в других органах. Результаты. С сентября 2019 по апрель 2025 г. включено 43 пациента, получавших сочетании ИКТИ и локальных методов (21 — в группу СТЛТ, 22 — в группу ИПП). В группе СТЛТ частота объективного ответа составила 42,8 %, шестимесячная ВБП (выживаемость без прогрессирования) — 66,7 % (95 % ДИ 42,5–82,5); медиана ВБП — 8,6 мес. (95 % ДИ 4,4–13,8), медиана общей выживаемости (ОВ) — 44,7 мес. (95 % ДИ 16,9–НД (не достигнута). В группе ИПП частота объективного ответа составила 45 %, шестимесячная ВБП — 72 % (95 % ДИ 48–86), медиана ВБП — 10,1 мес. (95 % ДИ 5,0–15,5), медиана ОВ не достигнута. Нежелательные явления (НЯ) 3–5-й степени наблюдались у 14,3 (СТЛТ) и 45,5 % (ИПП) пациентов. Выводы. Комбинация ингибиторов контрольных точек иммунитета с СТЛТ или ИПП демонстрирует высокую эффективность и удовлетворительную переносимость при метастатической увеальной меланоме для пациентов с различным объемом метастатического поражения и требует дальнейшего изучения.
- 27 December 2024
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 32 (4) , 517-527
Assessment of results of using three types of vascular access for isolated hepatic chemoperfusion
INTRODUCTION: Uveal melanoma (UM) is an oncological disease, which develops metastases mainly to the liver. One of treatments for this pathology is isolated hepatic chemoperfusion (IHCP). The implementation of this method requires surgical isolation of the liver from the systemic circulation and the use of a heart-lung machine. Due to a small number of observations of this treatment method in the world, the optimal vascular access for its implementation has not been determined so far. AIM: To analyze the in-hospital results of IHCP in patients with UM metastases performed from three different vascular accesses. MATERIALS AND METHODS: Over three years, 38 IHCP procedures were performed of the Kostroma Clinical Oncological Dispensary. Depending on the vessels into which the cannula for perfusion with Melphalan was inserted, patients were divided into 3 groups: group 1 with cava-porto-arterial access (perfusion into the inferior vena cava, portal vein, and common hepatic artery), n = 14; group 2 with cava-arterial access (perfusion into the inferior vena cava and common hepatic artery), n = 21; group 3 with a forced access, n = 3. The study took into account major complications: death, bleeding; and minor complications: tumor lysis syndrome, abscess of the left lobe of the liver, peritonitis, a systole, deep vein thrombosis of the lower limbs, hydrothorax, acute liver failure, anasarca, polyserositis, ischemic cholangiopathy, thrombosis of the common hepatic artery, detachment of the common hepatic artery intima. A combined endpoint was the achievement of at least one of the listed complications. In case of several complications in one patient, they were not summed up and were considered as ‘1’. RESULTS: In the postoperative period, the highest number of bleedings including those requiring revision, was noted in groups 1 and 3. The combined endpoint in the total sample made 42.11% and was lowest in group 2. Fatal outcomes were recorded in 3 cases (2 in group 1 and 1 in group 2), and were caused by increasing liver failure. CONCLUSION: The lowest number of complications IHCP was identified with cava-arterial access. Further continuation of the study is necessary to investigate the immediate and remote outcomes of IHCP.
- 27 December 2024
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 32 (4) , 517-527
Assessment of results of using three types of vascular access for isolated hepatic chemoperfusion
INTRODUCTION: Uveal melanoma (UM) is an oncological disease, which develops metastases mainly to the liver. One of treatments for this pathology is isolated hepatic chemoperfusion (IHCP). The implementation of this method requires surgical isolation of the liver from the systemic circulation and the use of a heart-lung machine. Due to a small number of observations of this treatment method in the world, the optimal vascular access for its implementation has not been determined so far. AIM: To analyze the in-hospital results of IHCP in patients with UM metastases performed from three different vascular accesses. MATERIALS AND METHODS: Over three years, 38 IHCP procedures were performed of the Kostroma Clinical Oncological Dispensary. Depending on the vessels into which the cannula for perfusion with Melphalan was inserted, patients were divided into 3 groups: group 1 with cava-porto-arterial access (perfusion into the inferior vena cava, portal vein, and common hepatic artery), n = 14; group 2 with cava-arterial access (perfusion into the inferior vena cava and common hepatic artery), n = 21; group 3 with a forced access, n = 3. The study took into account major complications: death, bleeding; and minor complications: tumor lysis syndrome, abscess of the left lobe of the liver, peritonitis, a systole, deep vein thrombosis of the lower limbs, hydrothorax, acute liver failure, anasarca, polyserositis, ischemic cholangiopathy, thrombosis of the common hepatic artery, detachment of the common hepatic artery intima. A combined endpoint was the achievement of at least one of the listed complications. In case of several complications in one patient, they were not summed up and were considered as ‘1’. RESULTS: In the postoperative period, the highest number of bleedings including those requiring revision, was noted in groups 1 and 3. The combined endpoint in the total sample made 42.11% and was lowest in group 2. Fatal outcomes were recorded in 3 cases (2 in group 1 and 1 in group 2), and were caused by increasing liver failure. CONCLUSION: The lowest number of complications IHCP was identified with cava-arterial access. Further continuation of the study is necessary to investigate the immediate and remote outcomes of IHCP.
- Open Access
- 6 September 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (4)
Treatment of Metastatic Uveal Melanoma: Literature Review
Увеальная меланома редкая внутриглазная опухоль, несмотря на все успехи в лечении первичной опухоли, более чем у 50 % пациентов развивается метастатическая форма заболевания. Увеальная меланома отличается по своим молекулярно-биологическим особенностям (другие драйверные мутации, меньшая мутационная нагрузка) от меланомы кожи, и если для меланомы кожи достигнуты определённые успехи в лечении (таргетная терапия, иммунотерапия), то для увеальной меланомы продолжаются поиски новых мишеней и подходов. В статье приведены исследования, отражающие эффективность и безопасность основных системных и локальных методов лечения, а также набирающих в последнее время популярность комбинированных подходов в лечении метастатической увеальной меланомы.
- 6 September 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (4)
Open AccessTreatment of Metastatic Uveal Melanoma: Literature Review
Увеальная меланома редкая внутриглазная опухоль, несмотря на все успехи в лечении первичной опухоли, более чем у 50 % пациентов развивается метастатическая форма заболевания. Увеальная меланома отличается по своим молекулярно-биологическим особенностям (другие драйверные мутации, меньшая мутационная нагрузка) от меланомы кожи, и если для меланомы кожи достигнуты определённые успехи в лечении (таргетная терапия, иммунотерапия), то для увеальной меланомы продолжаются поиски новых мишеней и подходов. В статье приведены исследования, отражающие эффективность и безопасность основных системных и локальных методов лечения, а также набирающих в последнее время популярность комбинированных подходов в лечении метастатической увеальной меланомы.
- 19 June 2024
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 40 (6) , 675-683
One year outcomes following of carotid endarterectomy in different age groups: Russian multicenter study
Introduction This is a retrospective analysis of the results of carotid endarterectomy (CEA) in different age groups. Methods This cohort, comparative, retrospective, open-label study for the period from 2008 to 2020 included 7248 patients with hemodynamically significant stenoses of the internal carotid artery (ICA), who underwent CEA. According to the classification of the World Health Organization, patients were divided into groups depending on age: up to 44 years—young age (n = 84); 45–60 years—middle age (n = 1635); 61–75—elderly age (n = 4817); over 75 years—senile age (n = 712). Results In terms of the frequency of hospital complications, the group of patients over 75 years of age experienced the largest number of cardiovascular events. One year after surgery, there were no significant differences in the incidence of complications between groups: death (group 1, 1.2%; group 2, 0.5%; group 3, 0.4%; group 4, 1%; p = 0.14), myocardial infarction (group 1, 1.2%; group 2, 0.3%; group 3, 0.14%; group 4, 0.3%; p = 0.12), stroke (group 1, 0%; group 2, 0.3%; group 3, 0.1%; group 4, 0.4%; p = 0.32). Conclusion The largest number of adverse cardiovascular events after CEA are observed among patients over 75 years of age, which is due to the high frequency of multivessel coronary lesions, atrial fibrillation, and the severity of the comorbidities. One year after surgery, there were no significant differences in the incidence of complications between groups.
- 19 June 2024
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 40 (6) , 675-683
One year outcomes following of carotid endarterectomy in different age groups: Russian multicenter study
Introduction This is a retrospective analysis of the results of carotid endarterectomy (CEA) in different age groups. Methods This cohort, comparative, retrospective, open-label study for the period from 2008 to 2020 included 7248 patients with hemodynamically significant stenoses of the internal carotid artery (ICA), who underwent CEA. According to the classification of the World Health Organization, patients were divided into groups depending on age: up to 44 years—young age (n = 84); 45–60 years—middle age (n = 1635); 61–75—elderly age (n = 4817); over 75 years—senile age (n = 712). Results In terms of the frequency of hospital complications, the group of patients over 75 years of age experienced the largest number of cardiovascular events. One year after surgery, there were no significant differences in the incidence of complications between groups: death (group 1, 1.2%; group 2, 0.5%; group 3, 0.4%; group 4, 1%; p = 0.14), myocardial infarction (group 1, 1.2%; group 2, 0.3%; group 3, 0.14%; group 4, 0.3%; p = 0.12), stroke (group 1, 0%; group 2, 0.3%; group 3, 0.1%; group 4, 0.4%; p = 0.32). Conclusion The largest number of adverse cardiovascular events after CEA are observed among patients over 75 years of age, which is due to the high frequency of multivessel coronary lesions, atrial fibrillation, and the severity of the comorbidities. One year after surgery, there were no significant differences in the incidence of complications between groups.
- Open Access
- 19 May 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2S) , 5756
Fourth consecutive emergency thrombectomy followed by femoral distal popliteal bypass in a patient with type VI popliteal artery entrapment syndrome: a case report
The article describes a case of the fourth consecutive emergency thrombectomy for popliteal and tibial artery thrombosis, followed by femoral distal popliteal bypass with a reversed vein in a patient with I. I. Zatevakhin grade 2B acute limb ischemia. The cause of repeated thrombosis type VI popliteal artery entrapment syndrome.
- 19 May 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2S) , 5756
Open AccessFourth consecutive emergency thrombectomy followed by femoral distal popliteal bypass in a patient with type VI popliteal artery entrapment syndrome: a case report
The article describes a case of the fourth consecutive emergency thrombectomy for popliteal and tibial artery thrombosis, followed by femoral distal popliteal bypass with a reversed vein in a patient with I. I. Zatevakhin grade 2B acute limb ischemia. The cause of repeated thrombosis type VI popliteal artery entrapment syndrome.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (5)
Simultaneous thyroidectomy for follicular adenocarcinoma and subclavian-carotid prosthetics
This article describes a clinical case of treatment of a 74-year-old patient with concomitant pathology: occlusion of the right common carotid artery and malignant neoplasm of the thyroid gland. Surgical intervention was performed in the scope of subclavian-carotid prosthesis and thyroidectomy. The postoperative period was uneventful. The patient was discharged from the hospital in satisfactory condition on the 7th day after surgery.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (5)
Simultaneous thyroidectomy for follicular adenocarcinoma and subclavian-carotid prosthetics
This article describes a clinical case of treatment of a 74-year-old patient with concomitant pathology: occlusion of the right common carotid artery and malignant neoplasm of the thyroid gland. Surgical intervention was performed in the scope of subclavian-carotid prosthesis and thyroidectomy. The postoperative period was uneventful. The patient was discharged from the hospital in satisfactory condition on the 7th day after surgery.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (3)
Combined operation: nephrectomy for renal cell cancer and bifurcation aorto-femoral prosthety
This article describes a clinical case of treatment of a 67-year-old patient with Leriche syndrome, chronic ischemia of the lower extremities of III degree according to A.V. Pokrovsky, and renal cell cancer. Due to the presence of pain in the lower extremities at rest and hematuria, a combined operation was performed: right nephrectomy with bifurcation aortofemoral replacement through a median laparotomy. The postoperative period was uneventful. The patient was discharged from the hospital in satisfactory condition on the 14th day after surgery.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (3)
Combined operation: nephrectomy for renal cell cancer and bifurcation aorto-femoral prosthety
This article describes a clinical case of treatment of a 67-year-old patient with Leriche syndrome, chronic ischemia of the lower extremities of III degree according to A.V. Pokrovsky, and renal cell cancer. Due to the presence of pain in the lower extremities at rest and hematuria, a combined operation was performed: right nephrectomy with bifurcation aortofemoral replacement through a median laparotomy. The postoperative period was uneventful. The patient was discharged from the hospital in satisfactory condition on the 14th day after surgery.
- 18 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (2)
Modern treatment methods for patients with liver metastases from uveal melanoma
Uveal melanoma is a rare malignant neoplasm originating from the uveal tract of the eye. The liver is the most common site of metastasis, occurring in 70—90% of cases and becoming the sole site of metastasis in approximately 50% of observations. This literature review presents modern methods for treating liver metastases from uveal melanoma: immunotherapy, targeted therapy, oncolytic adenovirus therapy, chemoembolization, transarterial chemoembolization, drug-eluting bead therapy, immunoembolization, radioembolization, thermal ablation, isolated hepatic perfusion. The conclusion is drawn about the highest efficacy, safety, and availability of isolated hepatic perfusion compared to other treatment methods.
- 18 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (2)
Modern treatment methods for patients with liver metastases from uveal melanoma
Uveal melanoma is a rare malignant neoplasm originating from the uveal tract of the eye. The liver is the most common site of metastasis, occurring in 70—90% of cases and becoming the sole site of metastasis in approximately 50% of observations. This literature review presents modern methods for treating liver metastases from uveal melanoma: immunotherapy, targeted therapy, oncolytic adenovirus therapy, chemoembolization, transarterial chemoembolization, drug-eluting bead therapy, immunoembolization, radioembolization, thermal ablation, isolated hepatic perfusion. The conclusion is drawn about the highest efficacy, safety, and availability of isolated hepatic perfusion compared to other treatment methods.
- Open Access
- 20 November 2023
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in EMERGENCY MEDICAL CARE
- Vol. 24 (3) , 65-69
Hybrid brain and myocardial revascularization: carotid reendarterectomy for restenosis + stenting of the left coronary artery
A clinical case of hybrid revascularization of the brain and myocardium was demonstrated in the volume: percutaneous coronary intervention of the left coronary artery by the method of Culote and carotid reendarterectomy using a temporary shunt. This surgical intervention was accompanied by a high level of complexity. The implementation of this method of treatment allowed to prevent the development of severe complications of the brain and myocardium.
- 20 November 2023
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in EMERGENCY MEDICAL CARE
- Vol. 24 (3) , 65-69
Open AccessHybrid brain and myocardial revascularization: carotid reendarterectomy for restenosis + stenting of the left coronary artery
A clinical case of hybrid revascularization of the brain and myocardium was demonstrated in the volume: percutaneous coronary intervention of the left coronary artery by the method of Culote and carotid reendarterectomy using a temporary shunt. This surgical intervention was accompanied by a high level of complexity. The implementation of this method of treatment allowed to prevent the development of severe complications of the brain and myocardium.